CSIMarket Company Name, Ticker, Suppliers, else..
 
Rezolute Inc   (RZLT)
Other Ticker:  
 
 
Price: $0.8066 $0.03 4.482%
Day's High: $0.82 Week Perf: 4.1 %
Day's Low: $ 0.74 30 Day Perf: -20.92 %
Volume (M): 54 52 Wk High: $ 2.90
Volume (M$): $ 44 52 Wk Avg: $1.77
Open: $0.82 52 Wk Low: $0.10



 Market Capitalization (Millions $) 41
 Shares Outstanding (Millions) 51
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -56
 Cash Flow (TTM) (Millions $) -146
 Capital Exp. (TTM) (Millions $) 0

Rezolute Inc
Rezolute Inc is a clinical-stage biopharmaceutical company that is focused on the development of drugs for the treatment of rare and metabolic diseases. The company's mission is to develop and commercialize therapies that can improve the lives of patients who suffer from rare diseases.

Founded in 2010, Rezolute Inc is headquartered in Redwood City, California. The company has a highly experienced management team that consists of industry veterans with a track record of success in drug development and commercialization.

Rezolute Inc is primarily focused on the development of two drug candidates, RZ358 and RZ40 RZ358 is a potential treatment for congenital hyperinsulinism (CHI), a rare genetic disorder that affects infants and children. RZ402 is a potential treatment for diabetic foot ulcers (DFU), a complication of diabetes that can lead to amputation.

The company's lead drug candidate, RZ358, is currently in a Phase 2b clinical trial for the treatment of CHI. Rezolute Inc has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for RZ358.

RZ402 is currently in pre-clinical development for the treatment of DFU. The company has received Orphan Drug Designation from the FDA for RZ40

Rezolute Inc has a partnership with Teva Pharmaceuticals, a leading global pharmaceutical company, for the development and commercialization of RZ358. The partnership includes an up-front payment to Rezolute Inc, as well as development and commercialization milestones.

In addition to its drug development programs, Rezolute Inc has a research collaboration with the Stanford University School of Medicine on the development of an implantable insulin pump for the treatment of diabetes.

Overall, Rezolute Inc is a promising biopharmaceutical company that is focused on developing innovative therapies for patients who suffer from rare and metabolic diseases. With its experienced management team, strong pipeline of drug candidates, and strategic partnerships, the company is well positioned for future success in the industry.


   Company Address: 275 Shoreline Drive, Suite 500 Redwood City 94065 CA
   Company Phone Number: 206-4507   Stock Exchange / Ticker: NASDAQ RZLT
   RZLT is expected to report next financial results on February 09, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Conduit Pharmaceuticals Inc

Conduit Pharmaceuticals Inc. Records Operating Shortfall in Q3 2023 but Reveals Promising Financial Indicators



As the earnings cycle for the third quarter of 2023 unfolds, various industries are reporting their financial results. One notable sector is Major Pharmaceutical Preparations, with Conduit Pharmaceuticals Inc being among the corporations announcing its numbers. Despite the absence of realized products and services, the company reported an operating shortfall of $-1.069 million during the July to September 30, 2023 period. However, a closer look at the financials reveals positive indicators, including a significant increase in net profits compared to the previous year. This article aims to analyze and contextualize the financial results of Conduit Pharmaceuticals Inc.
Financial Performance and Stakeholder Expectations:
During the current reporting period, Conduit Pharmaceuticals Inc faced an operating shortfall of $-1.069 million. This unfavorable figure, suggesting a loss for the company, signals the need for additional revenue sources to be explored as soon as possible. However, despite the current financial challenges, stakeholders seem less concerned about the organization's operational excellence and recent developments.
Ayala Pharmaceuticals Inc

ADXS Surpasses Expectations with Strong Third Quarter Results, Drives Optimism in the Pharmaceutical Industry



In the Major Pharmaceutical Preparations industry, where large companies dominate the market, smaller players are making their presence felt with promising results. One such company worth noting is ADXS, which recently announced an operating loss of $-7.131 million for the third quarter of 2023?a significant improvement compared to the same period last year, when the loss was $-7.291 million.
ADXS's positive results come as welcome news, particularly given the lack of easier references in the industry. This performance has generated optimism among market observers, who are now eyeing ADXS as a potential investment opportunity. The company's relentless pursuit of diverse corporate strategies aimed at ensuring new revenue streams has further bolstered this confidence.
Anebulo Pharmaceuticals Inc

Anebulo Pharmaceuticals Inc Achieves Promising Improvement, Reporting Operating Loss of $-2.543678 Million in Q1 2024

Anebulo Pharmaceuticals Inc, a lesser-known player in the Major Pharmaceutical Preparations sector, recently published their financial numbers for the first quarter of 2024. In a positive surprise for investors and analysts, the company announced that it had realized an operating loss of -$2.543678 million, an improvement from the previous year's operating loss of -$2.612047 million.
What is particularly noteworthy about this improvement is the decrease in diminishing returns, from -$2.612 million in the first quarter of 2023 to -$2.481 million in the same period this year. This suggests that Anebulo Pharmaceuticals Inc is making progress towards becoming an exceptional company in the Healthcare sector.
Qualigen Therapeutics Inc

Lackluster revenue at the Qualigen Therapeutics Inc in the most recent fiscal period

Qualigen Therapeutics Inc stock has seen some fluctuations in recent trading days. However, over the last five trading days, the stock experienced a solid gain of 7.2%. This positive movement comes after a slight decline of -1.91% during the preceding month.
Investors may also note that Qualigen Therapeutics Inc stock is currently trading only 12.3% above its 52-week low. This suggests that the stock has not seen significant upward momentum in recent months.
Onconova Therapeutics Inc

A deficit of $-0.23 per Share at the Onconova Therapeutics Inc amid the fiscal third quarter of 2023

Onconova Therapeutics Inc (ONTX) has recently reported its fiscal third-quarter results for 2023, and the numbers are not looking promising for the biopharmaceutical company. The company's financials reveal a decrease in earnings per share (EPS) compared to the same quarter last year, as well as a surge in deficit from the previous quarter.
For the fiscal third quarter of 2023, ONTX reported a loss of $-0.23 per share, which is slightly better than the loss of $-0.26 per share reported a year ago. However, compared to the previous quarter, the deficit has increased from $-0.20 per share. This indicates a concerning trend of worsening financial performance for the company.





 




Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com